KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Other Working Capital Changes (2016 - 2025)

Travere Therapeutics' Other Working Capital Changes history spans 13 years, with the latest figure at -$446000.0 for Q4 2025.

  • For Q4 2025, Other Working Capital Changes rose 74.35% year-over-year to -$446000.0; the TTM value through Dec 2025 reached $7.7 million, up 142.04%, while the annual FY2025 figure was $7.7 million, 142.04% up from the prior year.
  • Other Working Capital Changes reached -$446000.0 in Q4 2025 per TVTX's latest filing, down from $10.9 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $40.2 million in Q3 2021 to a low of -$11.2 million in Q3 2022.
  • Average Other Working Capital Changes over 5 years is $3.3 million, with a median of -$95500.0 recorded in 2023.
  • Peak YoY movement for Other Working Capital Changes: skyrocketed 1701.0% in 2021, then plummeted 781.96% in 2024.
  • A 5-year view of Other Working Capital Changes shows it stood at -$1.9 million in 2021, then surged by 860.6% to $14.1 million in 2022, then crashed by 98.19% to $255000.0 in 2023, then plummeted by 781.96% to -$1.7 million in 2024, then skyrocketed by 74.35% to -$446000.0 in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Other Working Capital Changes are -$446000.0 (Q4 2025), $10.9 million (Q3 2025), and -$4.5 million (Q2 2025).